Posted in | News | Biofuels

China Takes the Lead in Bioethanol Patent Generation

Chemical Abstracts Service (CAS), the world's authority on chemical information, reports that in 2009, China surpassed all other countries in the production of bioethanol patents, emerging as the global leader in the commercialization of bioethanol research.

In the CAS Chemistry Research Report: China Takes Lead in the Commercialization of Bioethanol, CAS examines 40 years of scientific research into biofuel development. Their key finding is that although U.S. researchers continue to publish more scientific research about bioethanol than other countries, China now produces more bioethanol-related patents than anyone. Other important findings include:

  • The U.S. published 105 journal articles related to first- and second-generation bioethanol research in 2009, more than any other country.
  • However, in the same year, the State Intellectual Property Office (SIPO) of the People's Republic of China issued the most bioethanol-related patent documents (156).
  • From 2000 to 2009, global research literature on second-generation bioethanol (derived from non-food sources, such as wheat stalks) grew 586 percent, including patenting activity that skyrocketed 2,341 percent.
  • Research into second-generation bioethanol significantly outpaced examination of first-generation (derived from edible feedstocks) and third-generation (derived from algae) bioethanol.
  • U.S. researchers are foremost within the newest category of bioethanol research: third-generation, or algae-based, bioethanol.

"The global research focus on second-generation bioethanol shows a rising interest in a category of fuels widely considered more sustainable, affordable, and environmentally friendly than bioethanol available today," said Christine McCue, vice president of marketing at CAS.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.